KELSEY ALLEN: Open Payments
NPI 1518592963 · NORTHFIELD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$422 in 27 payments from 10 companies in 2025. Trend: 2023 $1,403 · 2024 $228 · 2025 $422
Food & beverage: $422
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $143 |
| Novo Nordisk Inc | 4 | $76 |
| Amgen Inc. | 4 | $71 |
| Lundbeck LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| PFIZER INC. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
Products named: OTEZLA, VRAYLAR, REXULTI, Ozempic, TEFLARO, Wegovy, UBRELVY, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
